Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation.

Familial cancer - 1 Jan 2005

Metcalfe Kelly A, Snyder Carrie, Seidel Jennifer, Hanna Danielle, Lynch Henry T, Narod Steven

Abstract excerpt

PURPOSE: The purpose of this study was to assess women's knowledge about tamoxifen, to examine the frequency of tamoxifen usage and other preventive measures in BRCA1/2 mutation carriers, and to document women's concerns about taking tamoxifen for chemoprevention. METHODS: One hundred and twenty five women with known BRCA1 or BRCA2 mutation and with no prior diagnosis of breast or ovarian cancer were identified...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticarcinogenic Agents
Share to Chemoprevention

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Genetic Counseling

Share to Health Knowledge, Attitudes, Practice

Share to Patient Education as Topic

Share to Tamoxifen

Source

Identifiers

PMID: 15951959
DOI: 10.1007/s10689-005-4215-3

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation.PMID 15951959Read ↗

Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation.Semantic proximity Read ↗

Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history.Semantic proximity Read ↗

Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation.Semantic proximity Read ↗

Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.Semantic proximity Read ↗

BRCA mutation carriers' perceptions on postmenopausal hormone therapy: An Italian study.Semantic proximity Read ↗

Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers.Semantic proximity Read ↗

Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy.Semantic proximity Read ↗

Should you be taking tamoxifen?Semantic proximity Read ↗

Hormone Therapy in Breast Cancer Survivors and Those at High Risk for Breast Cancer.Semantic proximity Read ↗

Barriers to hormone therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers.Semantic proximity Read ↗

Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.Semantic proximity Read ↗

Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.